AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THESAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETINGCD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELLACUTE LYMPHOBLASTIC LEUKAEMIA
MD Anderson Study Status
This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.